New cancer drug trial paused after early safety testing
NCT ID NCT04418167
Summary
This is an early-stage study to test the safety and find the right dose of a new drug called JSI-1187. It is being tested alone and in combination with an existing drug, dabrafenib, in adults with advanced solid tumors that have specific genetic changes. The trial is currently suspended, and its main goal is to see how well the body tolerates the treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
-
Mayo Clinic Cancer Center
Phoenix, Arizona, 85054, United States
-
Mayo Clinic Cancer Center
Jacksonville, Florida, 32224, United States
-
Mayo Clinic Cancer Center
Rochester, Minnesota, 55905, United States
-
University of Arizona Comprehensive Cancer Center
Tucson, Arizona, 85724, United States
-
University of California Helen Diller Family Comprehensive Cancer Center
San Francisco, California, 94158, United States
Conditions
Explore the condition pages connected to this study.